Eli Lilly spotlights early oncology in first pipeline review since R&D shift
Two weeks into the Josh Bilenker era at Eli Lilly, the legacy pharma was excited to spotlight three early-stage
Related Articles
Exclusive: FDA blocks drug and device reviewers from taking HHS’ buyout offer
The FDA told staff on Monday that reviewers of medical products and inspectors of manufacturing facilities cannot take the buyout offer circulated on Friday from…
Moderna stands by its Covid vaccine IP after decision axing two patents
Moderna says its long-running patent dispute with Pfizer and BioNTech isn’t over even after a decision by an administrative tribunal that invalidated two of its…
Sanofi faces $250M charge after J&J-partnered vaccine flunks late-stage test
Sanofi faces $250M charge after E. coli vaccine developed with J&J fails Phase 3 trial; study ends early due to insufficient efficacy in preventing invasive…
Judge halts some NIH cuts after 22 states sue
A federal court in Massachusetts temporarily blocked the Trump administration’s new cap on indirect cost reimbursements for NIH grant recipients within the 22 states that…
AbbVie wins FDA approval for new antibiotic to treat complex intra-abdominal infections
The FDA has approved Emblaveo in combination with metronidazole for complicated intra-abdominal infections, providing a new tool to fight antimicrobial resistance.
The top 100 biotech VCs
Every year Chris Dokomajilar at DealForma and Endpoints founding editor John Carroll collaborate on identifying the top 100 biotech VCs in operation, based on the…
Belgian regulator recommends blocking Indian drugmaker’s API production
Indian drugmaker Maithili Life Sciences has received a non-compliant report from the Brussels-based Federal Agency for Medicines and Health Products for issues related to APIs.
Major FDA staff cuts would slow drug reviews, experts say
The Trump administration’s reported plans to potentially lay off thousands of FDA employees could slow the agency’s reviews of new drugs, experts say, in addition…
Bain buys 340-year-old pharma company to fast-track Japan’s drug development
Private equity firm expects $3.3bn acquisition of Tanabe will get boost from eased approval process for new medicine
Small personalized vaccine trial sees progress in late-stage kidney cancer
All nine late-stage kidney cancer patients in a Phase 1 trial of a personalized vaccine remained cancer-free after more than three years of receiving treatment,…
